Tumor Board: Expert Insights on Managing Classical EGFR Mutations, EGFR Exon 20 Insertions, and Atypical EGFR Mutations in Metastatic NSCLC

Thanks for your interest in this podcast. Please read this important program information before listening. 

Episode Description
In this podcast, experts Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; and Julia Rotow, MD; discuss the latest evidence in managing EGFR-mutated non–small cell lung cancer (NSCLC), with a focus on personalized treatment strategies based on factors such as molecular profile, disease burden, and patient fitness. 

Learning Objectives 
Upon successful completion of this activity, you should be better prepared to:
·  Outline current and emerging treatment strategies for EGFR-mutated metastatic NSCLC

·  Integrate recent data and guideline-based recommendations when developing personalized care plans for patients with EGFR-mutated metastatic NSCLC

·  Identify appropriate strategies for the prevention and management of toxicities associated with EGFR-targeting therapies for metastatic NSCLC

Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Black Diamond Therapeutics.

Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions on How to Receive Credit
1.       Listen to this podcast in its entirety. 
2.       Go to gotoper.com/credit and enter code: 7235
3.       Answer the evaluation questions.
4.       Request credit using the drop-down menu.

You may immediately download your certificate.

Chair:
Balazs Halmos, MD, MS 
Professor of Clinical Medicine 
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics 
Albert Einstein College of Medicine/Montefiore Medical Center 
Bronx, NY

Disclosures: Consultant: Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Genentech, GSK, Johnson & Johnson, Merck, Pfizer, Takeda; DSMC: Apollomics, BMS, City of Hope, eFFECTOR, Nuvalent, TPT; Research grant (paid to institution): AbbVie, Advaxis, Amgen, ArriVent, AstraZeneca, BeiGene, Black Diamond Therapeutics, BMS, Boehringer Ingelheim, Daiichi Sankyo, Forward Pharma, GSK, Janssen, Merck, Numab, Pfizer.

Faculty
Enriqueta Felip, MD, PhD
Professor of Medicine, Universitat Autònoma de Barcelona (UAB)
Section in Chief, Medical Oncology Department 
Director, Thoracic Oncology Unit 
Vall d’Hebron University Hospital 
Vall d’Hebron Institute of Oncology (VHIO) 
Barcelona, Spain

Disclosures: Consulting Fee: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daichii Sankyo, F. Hoffmann-La Roche, Gilead, Glaxo Smith Kline, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Turning Point; Independent Member of the Board: Grifols; Speaker’ Bureau: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Gilead, Janssen, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, PeerVoice, Pfizer, Regeneron, Takeda; Support for Attending Meetings/Travel: AstraZeneca, Johnson & Johnson, Roche.

Julia Rotow, MD
Assistant Professor
Harvard Medical School
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squib, Daiichi Sankyo, Genentech, Gilead, Jazz, Johnson & Johnson, Merus, Novocure, Pfizer; Contracted for Research (to institution): AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond Therapeutics, Blueprint Medicines, Duality, Enliven Therapeutics, EpimAb, Immunity Bio, LOXO Oncology, ORIC Pharmaceuticals, RedCloud Bio, Regeneron, Summit, Synthekine; Honoraria: AstraZeneca, Daiichi Sankyo, Pfizer.

Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on biomarker testing and managing patients with atypical EGFR mutations, go to https://www.gotoper.com/annual-oncology-meeting-25-egfrnsclc-activity

Release Date
July 30, 2025

Expiration Date
July 30, 2026